Browse the detailed record of transactions filed by Mathew Aby J., Executive Vice President and Chief Scientific Officer. Director active across 1 companies, notably Biolife Solutions INC. Aggregated, 46 reports have been published. Total volume traded: €699k. The latest transaction was disclosed on 28 June 2022 — Cession. Regulator: SEC (Form 4). The full history is free.
25 of 46 declarations
Aby J. Mathew, PhD, serves as Executive Vice President and Chief Scientific Officer at BioLife Solutions Inc., where he holds one of the company’s most prominent scientific leadership roles. He joined BioLife in 2000 and advanced through positions of increasing responsibility, including Senior Vice President and Chief Technology Officer, before being appointed Chief Scientific Officer in December 2019. BioLife identifies him as a founding team member and as a co-developer of the company’s HypoThermosol® and CryoStor® biopreservation platforms, which are central to its product portfolio. ([biolifesolutions.com](https://www.biolifesolutions.com/company/leadership/?utm_source=openai)) His career has been closely tied to the development of biopreservation technologies for research, GMP, clinical, and commercial applications. BioLife says he helped establish the company’s initial manufacturing and quality systems, indicating a role that combined scientific innovation with operational and manufacturing discipline. The company also describes him as a recognized thought leader in cell and tissue biopreservation, with expertise spanning regenerative medicine, cell processing, and cold-chain biological logistics. ([prnewswire.com](https://www.prnewswire.com/news-releases/biolife-solutions-unveils-the-aby-j-mathew-center-for-biopreservation-excellence-302621082.html?utm_source=openai)) Academically, he is reported by company and market sources to hold a BS in Microbiology and a PhD in Cell & Molecular Biology / Biological Sciences. His expertise centers on biopreservation science, process development, and the adoption of clinical-grade solutions for advanced therapy workflows. BioLife also highlights multiple issued and pending patents, along with numerous peer-reviewed publications, underscoring his contribution to intellectual property and industry best practices. ([biolifesolutions.com](https://www.biolifesolutions.com/company/leadership/?utm_source=openai)) In his current role, Mathew has helped guide BioLife’s growth into a broader bioproduction tools company serving the cell and gene therapy market. A notable recent recognition of his contribution came in 2025, when BioLife opened the Aby J. Mathew Center for Biopreservation Excellence in his honor, citing his foundational role in the company’s technologies and scientific development. ([prnewswire.com](https://www.prnewswire.com/news-releases/biolife-solutions-unveils-the-aby-j-mathew-center-for-biopreservation-excellence-302621082.html?utm_source=openai))